Human medicines European public assessment report (EPAR): Azopt, brinzolamide, Date of authorisation: 09/03/2000, Revision: 30, Status: Authorised

Human medicines European public assessment report (EPAR): Xadago, safinamide, Date of authorisation: 23/02/2015, Revision: 16, Status: Authorised

Third European Medicines Agency (EMA) and IPFA - PPTA global bilateral meeting, European Medicines Agency, Amsterdam, the Netherlands, from 9 February 2026, 13:00 (CET) to 9 February 2026, 15:00 (CET)

PRAC recommendations on signals adopted at the 12-15 January 2026 PRAC meeting

New product information wording: extracts from PRAC recommendations on signals adopted at the 12-15 January 2026 PRAC

Concept paper on the revision of the guidelines on Good Manufacturing Practice for medicinal products - Annex 15 - Qualification and validation

List of signals discussed at PRAC since September 2012

Human medicines European public assessment report (EPAR): Uptravi, selexipag, Date of authorisation: 12/05/2016, Revision: 19, Status: Authorised

Guideline on good pharmacovigilance practices (GVP): Product- or population-specific considerations III: Pregnant and breastfeeding women and their children exposed in utero or via breastmilk - with tracked changes

Comments received from public consultation on good pharmacovigilance practices (GVP) Product- or Population-Specific Considerations III: Pregnant and breastfeeding women (EMA/653036/2019)